My watch list
my.chemeurope.com  
Login  

Certolizumab pegol



Certolizumab pegol (CDP870) (proposed tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.

Additional recommended knowledge

It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.

In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.

References

  1. ^ Sandborn WJ, Feagan BG, Stoinov S, et al (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228-38. doi:10.1056/NEJMoa067594. PMID 17634458.
  2. ^ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy 5 (4): 601-6. doi:10.1517/14712598.5.4.601. PMID 15934837.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Certolizumab_pegol". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE